TY  - JOUR
T1  - INappropriate data and measures lead to questionable conclusions—reply
AU  - Gibbons RD, Brown C, Hur K, Davis JM, Mann J
Y1  - 2013/01/01
N1  - 10.1001/jamapsychiatry.2013.749
JO  - JAMA Psychiatry
SP  - 121
EP  - 123
VL  - 70
IS  - 1
N2  - 
Spielmans and colleagues state that study LYAQ included atomoxetine as a treatment and should have been excluded. In fact, the first 2 active treatment visits did not include atomoxetine and our analysis of the data from this study was restricted to this period (days 1-42 postbaseline depending on the subject). Furthermore, although patients in this study had comorbidities including attention-deficit/hyperactivity disorder, the majority (81%) of patients had a depressive disorder. As such, our inclusion of this study was scientifically appropriate.

SN  - 2168-622X
M3  - doi: 10.1001/jamapsychiatry.2013.749
UR  - http://dx.doi.org/10.1001/jamapsychiatry.2013.749
ER  -